Boehringer Filed NDA for Afatinib in Japan: Chairman

Andreas Barner, Chairman of the Board, Boehringer Ingelheim Boehringer Ingelheim (BI) has filed a new drug application (NDA) for its non-small-cell lung cancer treatment afatinib in Japan, the head of the German drug maker revealed on April 24, setting the...read more